CN114917345A - Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer - Google Patents
Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer Download PDFInfo
- Publication number
- CN114917345A CN114917345A CN202210544982.5A CN202210544982A CN114917345A CN 114917345 A CN114917345 A CN 114917345A CN 202210544982 A CN202210544982 A CN 202210544982A CN 114917345 A CN114917345 A CN 114917345A
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- soat1
- protein
- drug
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 title claims abstract description 47
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 title claims abstract description 46
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 45
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 45
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 230000008685 targeting Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 11
- 229940079593 drug Drugs 0.000 claims abstract description 51
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims abstract description 19
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims abstract description 19
- 230000003834 intracellular effect Effects 0.000 claims abstract description 16
- IHIUGIVXARLYHP-UXNJHFGPSA-N Evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2CC1CCC(C(O)=O)CC1 IHIUGIVXARLYHP-UXNJHFGPSA-N 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims description 19
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 230000031154 cholesterol homeostasis Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000009702 cancer cell proliferation Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 58
- 235000012000 cholesterol Nutrition 0.000 abstract description 21
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 abstract description 13
- 229950010046 avasimibe Drugs 0.000 abstract description 13
- 229960003401 ramipril Drugs 0.000 abstract description 10
- 239000013641 positive control Substances 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001840 cholesterol esters Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 40
- 238000003032 molecular docking Methods 0.000 description 14
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 12
- -1 Nevanimibe Chemical class 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 7
- IHIUGIVXARLYHP-YBXDKENTSA-N evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2C[C@H]1CC[C@H](C(O)=O)CC1 IHIUGIVXARLYHP-YBXDKENTSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- IMQSIXYSKPIGPD-YQRUMEKGSA-N filipin III Chemical compound CCCCC[C@@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-YQRUMEKGSA-N 0.000 description 3
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 108091006625 SLC10A6 Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 229950000005 evacetrapib Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- PKKNCEXEVUFFFI-UHFFFAOYSA-N nevanimibe Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(C=2C=CC(=CC=2)N(C)C)CCCC1 PKKNCEXEVUFFFI-UHFFFAOYSA-N 0.000 description 1
- 229940121467 nevanimibe Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 238000010570 post-docking Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a group of drugs or compounds targeting SOAT1 protein, which are Ramipril (Altage), ABT-737 and Evactrapib (LY 2484595). Experiments show that the medicine and the positive control medicine Avasimibe can inhibit the conversion of cholesterol to cholesterol ester by combining with SOAT1, and increase the intracellular cholesterol level. Further, cell proliferation experiments of the medicines on three cells, namely a liver cancer cell line HepG2, PLC and 97L show that the medicines can obviously inhibit the growth of liver cancer cells and obtain an IC50 value superior to that of a positive medicine, namely Avasimibe. The invention provides a new targeted medicament for treating liver cancer from the angle that the targeted SOAT1 protein influences the steady state of cholesterol, and provides a new direction for clinical treatment of liver cancer.
Description
The application is a divisional application of a compound which is invented and created with the application number of 202110371783.4, the application date of 2021, 04/7, and the name of the application is 'application of a compound targeting SOAT1 protein in the preparation of a medicament for preventing and/or treating liver cancer'.
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a group of micromolecular medicines of a targeted cholesterol steady-state target SOAT1 protein, which has a prospect of treating liver cancer.
Background
Cholesterol is an essential lipid component for maintaining cell homeostasis. It is a major component of cell membranes, in addition to being a precursor for the synthesis of bile acids, steroid hormones and vitamin D, is enriched in lipid rafts and plays an important role in cell signaling. Researches find that cholesterol metabolism reprogramming exists in the process of generating and developing tumor cells, the intracellular cholesterol level is obviously increased, and metabolites of the intracellular cholesterol level are abnormally accumulated. In the early stage, the research on the proteome and the phosphoproteome of 101 cases of early hepatocellular carcinoma and paired cancer-adjacent tissue samples in the subject group discovers that the patients with early hepatocellular carcinoma clinically considered at present can be divided into three proteome subtypes, and patients with different subtypes have different prognosis characteristics (S-I, S-II and S-III) and need different treatment schemes after operation. In particular, proteomic studies of patients with third-class hepatocellular carcinoma have found that the cholesterol metabolic pathway is reprogrammed, and the high expression of a candidate drug target cholesterol esterase (SOAT1) has the worst prognosis risk, which indicates that the SOAT1 protein plays an important role in regulating cholesterol homeostasis and in the development of liver cancer.
In recent years, development of anti-tumor drugs targeting the SOAT1 protein is also ongoing, for example, Avasimibe is first used as a lipid regulating drug for treating atherosclerosis, and is recently discovered to have a therapeutic effect on pancreatic cancer, liver cancer and the like; in addition, small molecules such as Nevanimibe, CL-976 and the like are reported to have a eutectic three-dimensional structure with SOAT1 protein and have the effect of inhibiting the activity of the protein. However, the studies are still in preclinical research, so that drug screening is performed around a target SOAT1 affecting cholesterol homeostasis, and a new small molecule with an anti-tumor effect is found by combining tumor cells and cholesterol homeostasis analysis and verification, so that a new direction is provided for targeted therapy of liver cancer.
Disclosure of Invention
The invention aims to provide a new application of a group of drugs/compounds targeting SOAT1 protein.
The new application of the drug/compound targeting the SOAT1 protein provided by the invention is the application of the drug/compound in preparing a drug for preventing and/or treating liver cancer.
The new application of the drug/compound targeting the SOAT1 protein provided by the invention is the application of the drug/compound in the preparation of liver cancer cell proliferation inhibitors.
The drug/compound targeting the SOAT1 protein is combined with the SOAT1 protein and inhibits the growth of hepatoma cells.
The invention also includes the use of drugs/compounds targeting the SOAT1 protein in:
1) preventing and/or treating liver cancer;
2) inhibiting proliferation of hepatocarcinoma cell.
The liver cancer cell can be HepG2, PLC/PRF/5(PLC) and MHCC97L (97L).
The drug/compound targeting the SOAT1 protein is specifically selected from at least one of the following: nilotinib (AMN-107), Ramipril (Alpace), ABT-737 and Evactrapib (LY 2484595).
Among them, Nilotinib (AMN-107), Cas No.: 641571-10-0, the structural formula is shown as follows:
ramipril (altace), Cas No.: 87333-19-5, the structural formula is as follows:
ABT-737, Cas No.: 852808-04-9, the structural formula is shown as follows:
evacetrrapib (LY2484595), CAS No.1186486-62-3, having the structural formula:
the Nilotinib (AMN-107) has obvious inhibition effect on three liver cancer cells HepG2, PLC and 97L, IC 50 448.5nM, 15.7. mu.M and 2.44. mu.M, respectively.
The Ramipril (Altace) has obvious inhibition effect on three liver cancer cells HepG2, PLC and 97L, and IC 50 96.8nM,25.1nM and 6.0. mu.M, respectively.
The ABT-737 has obvious inhibiting effect on three kinds of liver cancer cells HepG2, PLC and 97L, and IC 50 184.0nM, 3.3. mu.M and 2.1. mu.M, respectively.
The Evacet rapib (LY2484595) has obvious inhibition effect on three hepatoma cells HepG2, PLC and 97L, and IC 50 9.2. mu.M, 5.6. mu.M and 2.0. mu.M, respectively.
The invention also provides a product, which is characterized in that: the active ingredient of the product is at least one of Nilotinib (AMN-107), Ramipril (Alpace), ABT-737 and Evactrapib (LY 2484595).
The product has at least one of the following effects:
1) for preventing and/or treating liver cancer;
2) inhibiting proliferation of hepatocarcinoma cell.
Illustratively, the product may be a medicament or pharmaceutical formulation.
The product may contain, in addition to the active ingredient, suitable carriers or excipients. The carrier material herein includes, but is not limited to, water-soluble carrier materials (e.g., polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.), poorly soluble carrier materials (e.g., ethyl cellulose, cholesterol stearate, etc.), enteric carrier materials (e.g., cellulose acetate phthalate, carboxymethyl cellulose, etc.). Among these, water-soluble carrier materials are preferred. The materials can be prepared into various dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections and the like. Can be common preparation, sustained release preparation, controlled release preparation and various microparticle drug delivery systems. In order to prepare the unit dosage form into tablets, various carriers well known in the art can be widely used. Examples of the carrier are, for example, diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate and the like; wetting agents and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrating agents such as dried starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid ester, sodium dodecylsulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors such as sucrose, glyceryl tristearate, cacao butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammonium salts, sodium lauryl sulfate and the like; lubricants, for example, talc, silica, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, and the like. The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets. In order to prepare the dosage form for unit administration into a pill, various carriers well known in the art can be widely used. Examples of the carrier are, for example, diluents and absorbents such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc and the like; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrating agents, such as agar powder, dried starch, alginate, sodium dodecylsulfate, methyl cellulose, ethyl cellulose, etc. In order to prepare the unit dosage form into suppositories, various carriers known in the art can be widely used. As the carrier, for example, polyethylene glycol, lecithin, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semisynthetic glycerides and the like are exemplified. In order to prepare the unit dosage form into preparations for injection, such as solutions, emulsions, lyophilized powders and suspensions, all diluents commonly used in the art, for example, water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc., can be used. In addition, for the preparation of isotonic injection, sodium chloride, glucose or glycerol may be added in an appropriate amount to the preparation for injection, and conventional cosolvents, buffers, pH adjusters and the like may also be added. In addition, colorants, preservatives, flavors, flavorings, sweeteners, or other materials may also be added to the pharmaceutical preparation, if desired. The preparation can be used for injection administration, including subcutaneous injection, intravenous injection, intramuscular injection, intracavity injection and the like; for luminal administration, such as rectally and vaginally; administration to the respiratory tract, e.g., nasally; administration to the mucosa.
The invention also provides a method for preventing and/or treating liver cancer, which comprises the following steps: administering the drug/compound targeting the SOAT1 protein to a recipient animal or human for the prevention and/or treatment of liver cancer.
In the present invention, the animal may be a mammal.
The four drugs/compounds described in this invention can bind to the SOAT1 protein and affect intracellular cholesterol homeostasis.
The four medicines or compounds can obviously inhibit the growth of hepatoma carcinoma cells, compared with Avasimibe, Nilotinib (AMN-107), Ramipril (Altance) and ABT-737 have better effects than positive medicine Avasimibe, and the Evactrapib has basically the same effect as the positive medicine. Cholesterol homeostasis experiments also show that these drugs, by binding to SOAT1, inhibit the conversion of cholesterol to cholesteryl esters, and elevate intracellular cholesterol levels; and can achieve the effect of increasing intracellular cholesterol at lower drug concentration. The invention provides a new liver cancer treatment targeted drug from the angle that targeted SOAT1 protein influences cholesterol steady state, and provides a new direction for clinical treatment of liver cancer.
Drawings
Figure 1 is a high throughput screen based on the SOAT1 target protein. Several drugs or compounds are shown to bind to the binding pocket and potential binding site of the SOAT1 protein.
FIG. 2 is the liver cancer cell viability assay by small molecule screening. The graph shows the cell viability measured with CCK-8 after 24h and Avasimibe as a positive control given two concentrations of 2. mu.M and 20. mu.M, respectively, for the four drugs in HepG2 cells.
FIG. 3 shows the activity IC of Nilotinib on three liver cancer cells HepG2, PLC and 97L 50 And (4) measuring.
FIG. 4 shows the cell viability IC of Ramipril on three liver cancer cells HepG2, PLC and 97L 50 And (4) measuring.
FIG. 5 shows that ABT-737 has three kinds of liver cancer cell HepG2, PLC and 97L cell activity IC 50 And (4) measuring.
FIG. 6 shows that Evacetrapib has activity IC on three liver cancer cells HepG2, PLC and 97L 50 And (4) measuring.
FIG. 7 is a drug versus cell cholesterol homeostasis assay. The graphic representation is 2 times IC of the four drugs 50 At the dosing concentration, intracellular cholesterol staining was performed with filibin, and Avasimibe was the positive control.
Fig. 8 is a comparison of the activity of the four drugs in HepG2 cells with the positive control Avasimibe.
Detailed Description
The present invention will be further illustrated with reference to the following specific examples, but the present invention is not limited to the following examples. The method is a conventional method unless otherwise specified. The starting materials are commercially available from the open literature unless otherwise specified.
Nilotinib (AMN-107) used in the examples below was purchased from Selleck, catalog No. S1033; ramipril (Altace) from Selleck, catalog number S1793, ABT-737 from Selleck, catalog number S1002; evacet rapib (LY2484595) from Selleck, catalog number S2825; avasimibe was purchased from Selleck, catalog number S2187.
The liver cancer cells HepG2 used in the examples described below were purchased from ATCC, product number ATCC HB-8065; PLC was purchased from ATCC, product number ATCC CRL-8024; 97L was purchased from ATCC (agency of Wuhan Protech, Bio Inc.), product number CL-0497.
Example 1: high throughput screening based on SOAT1 target proteins
The three-dimensional crystal structure of the SOAT1 protein described in this example is derived from RCSB PDB database, two models of SOAT1 protein PDB code 6L47 and 6VUM were selected for high-throughput ligand screening, and the small molecule database is derived from FDA and select compounds library. The docking software comprises four docking methods (two docking methods of glide fraction SP and XP) of three software including AutoDock 4.2, sybyl 2.0 and glide to carry out primary screening on all the compounds to be screened.
Specifically, before molecular docking, docking pockets were first defined, and the experiment mainly used the hydrophobic pocket of the SOAT1 protein, the C channel, the T channel, and the NTD end binding pocket as the main active docking pockets. For AutoDock 4.2 and sybyl 2.0, a lattice was created around the four active pockets described above (set at a distance of about 15 angstroms in size) and added to SOAT1 and the compound to be docked by adding polar hydrogen and Gasteiger-Huckel partial charge. The conformational sampling of SOAT1 and the compound were set to be rigid and flexible, respectively. Genetic algorithms and empirical free energy functions are used to generate and account for docking gestures, respectively. For glide SP and XP patterns, protein and compound pre-treatments were as above, docking results were refined by post-docking energy minimization and docking results were evaluated by scoring functional glideScore. After all these docking steps are completed, the docking results will be merged, with the top 20% of compounds ranked in all docking tools and with a degree of aggregation greater than 80% being considered as potential active compounds. And then, further performing high-precision docking through gliedeocking, and performing visual display and mapping on the result in pymol software. The docking results of Nilottinib (AMN-107), Ramipril (Alpace), ABT-737, Evactrapib (LY2484595) and the positive control Avasimibe are shown in FIG. 1, and the docking scores of all the four drugs are smaller than those of the positive control, and show good binding with SOAT 1.
Example 2: screening of small molecules for determination of liver cancer cell viability
To explore the activity of the four screened compounds on hepatoma cells, we proceeded with cell viability assays.
The cells used in this example were HepG2 cells, and the test drugs were Nilotinib (AMN-107), Ramipril (Alrace), ABT-737 and Evactrapib (LY2484595), with an additional blank control and a positive control (Avasimibe). Specifically, the method comprises the following steps:
1) 8000/well HepG2 cells were seeded in 96-well plates in DMEM medium containing 10% fetal bovine serum at 37 deg.C with 5% CO 2 Culturing for 12-24 h in a culture environment, and adding the diluted medicine when the cells grow to about 70%.
2) The four drugs and positive control were diluted to 2. mu.M and 20. mu.M in cell culture medium, and DMSO was used as a blank control.
3) Old medium was removed and diluted drug (formulated in cell culture medium) was added to the 96-well plates containing cells and labeled, repeating in triplicate for each concentration.
4)37℃，5％CO 2 And continuously culturing for 24-48h in the culture environment, adding 10 mu L/hole of CCK-8 reagent, and continuously culturing for 1 h.
5) The absorbance of the incubated samples was measured at 450nM using a microplate reader, the data collected and plotted for analysis in a graphipad prism 9.0.
As shown in FIG. 2, Nilotinib (AMN-107), Ramipril (Alpace), ABT-737 and Evactrapib (LY2484595) can significantly inhibit the growth of HepG2 cells at both 2. mu.M and 20. mu.M concentrations.
Example 3: four screened drugs/compounds for three hepatoma cells IC 50 Measurement of
To further explore the activity of four compounds on hepatoma cells, we performed cellular IC 50 And (4) measuring. Specifically, the method comprises the following steps:
1) 8000/well HepG2, PLC and 97L liver cancer cells are respectively planted in a 96-well plate, and are cultured for 12-24 hours in a DMEM culture medium containing 10% fetal calf serum at 37 ℃ in a 5% CO2 culture environment, and diluted medicines are added when the cells grow to about 70%.
2) The four drugs were diluted from 10mM to 100. mu.M, 50. mu.M, 25. mu.M, 10. mu.M, 5. mu.M, 1. mu.M, 100nM, 10nM, 1nM, 0 ten concentration points, respectively.
3) The old medium was removed and the diluted drug (media matched) was added to a 96-well plate containing HepG2, PLC and 97L hepatoma cells and labeled, each concentration being repeated in triplicate.
4)37℃，5％CO 2 And continuously culturing for 24-48h in the culture environment, adding 10 mu L/hole of CCK-8 reagent, and continuously culturing for 1 h.
5) The absorbance of the incubated sample was measured at 450nM in a microplate reader, the data collected and plotted in a graphipad prism 9.0.
IC measurements of several drugs in three cells 50 As shown in FIGS. 3 to 6, the cell growth inhibitory effect was excellent at a low drug concentration.
Example 4: drug-on-cell cholesterol homeostasis assay
This example is mainly used to investigate the effect of four compounds on intracellular Cholesterol of hepatoma carcinoma cells, and the method used is the phenanthroline III intracellular Cholesterol staining (Cholesterol cell-based detection assay kit, No. 10009779). The principle is that filipin III can bind to cholesterol on the membrane and emit blue light to develop color. While SOAT1 is an important intracellular cholesterol homeostasis regulatory protein that can convert cholesterol into cholesteryl ester, when SOAT1 is inhibited, the conversion of intracellular cholesterol into cholesteryl ester is limited, and intracellular cholesterol will rise. This experiment explores the effect of drugs on cellular cholesterol. Specifically, the method comprises the following steps:
1) 8000/well HepG2 was seeded in 96 well plates in DMEM medium containing 10% fetal calf serum at 37 deg.C with 5% CO 2 Culturing for 12-24 h in a culture environment, and adding the diluted medicine when the cells grow to about 70%.
2) The above Nilotinib (AMN-107), Ramipril (Alpace), ABT-737, Evactrapib (LY2484595) and Avasimibe were diluted to 1. mu.M, 200nM, 400nM, 20. mu.M and 10. mu.M, respectively (IC of each drug versus HepG 2) 50 Two times the dose).
3) Old media was removed and diluted drug (media-matched) was added to the cell-containing 96-well plates and labeled, each concentration being repeated in triplicate.
4)37℃，5％CO 2 And (4) continuously culturing for 12-24 h in the culture environment (the cells grow to about 70-80% and the best observation effect is obtained), and then dyeing is carried out according to the instruction of the cholesterol filipin III alcohol dyeing kit.
5) After removing the culture medium from the cultured cells, the cells were washed with PBS 3 times 50. mu.L of PBS buffer each time in a shaker at 100 rpm for 5 minutes at room temperature.
6) The washed HepG2 cells were fixed for 15 minutes at room temperature in a cell fixing solution (Item No. 10009866). Then, the mixture was washed 3 times with 50. mu.L of PBS buffer each time on a shaker at 100 rpm for 5 minutes.
7) The filipin III stock solutions were mixed at 1: 100 dilutions (Item No.10009868) were added to each well in 100. mu.L of diluted solution and incubated for 30-60min in the absence of light (note that this step was carried out in the absence of light as much as possible). Then, the mixture was washed 3 times with 50. mu.L of PBS buffer each time on a shaker at 100 rpm for 5 minutes.
8) And (3) observing the washed sample under a 20-time microscope, wherein the excitation wavelength is 340-380nm, the emission wavelength is 385-470nm, and collecting and arranging data.
As shown in FIG. 7, several drugs at the corresponding concentrations can significantly affect intracellular cholesterol levels. And The result is consistent with The result of a SOAT1 protein knock-down group (gene knock-down experiment, The expression of SOAT1 protein is interfered by sh-RNA which is purchased from sigma-aldrich company (http:// www.sigmaaldrich.com) in The USA, and The sequence of The SOAT1 sh-RNA is shown as 5'-CCGGTGGTCCATGACTGGCTATATTCTCGAGAATATAGCCAGTCATGGACCATTTTTTG-3'), which indicates that The drug targeting SOAT1 protein can cause The change of intracellular cholesterol.
In summary, the four disclosed drugs, Nilotinib (AMN-107), Ramipril (Altance), ABT-737, Evactrapib (LY2484595), bind to SOAT1 and thereby inhibit the conversion of cholesterol to cholesteryl esters, and increase intracellular cholesterol levels. They can obviously inhibit the growth of liver cancer cells and obtain IC superior to positive drug Avasimibe 50 Values (fig. 8). The invention provides a new liver cancer treatment targeted drug from the angle that targeted SOAT1 protein influences cholesterol steady state, and provides a new direction for clinical treatment of liver cancer.
Claims (10)
1. The application of the drug/compound targeting the SOAT1 protein in the preparation of the drug for preventing and/or treating liver cancer;
the drug/compound targeting the SOAT1 protein is selected from at least one of the following: ramipril (Altace), ABT-737 and Evactrapib (LY 2484595);
wherein, Ramipril (Altace), Cas No.: 87333-19-5, the structural formula is as follows:
ABT-737, Cas No.: 852808-04-9, the structural formula is shown as follows:
evacet rapib (LY2484595), CAS No.1186486-62-3, having the following structural formula:
2. the use of the drug/compound targeting SOAT1 protein according to claim 1 in the preparation of inhibitors of liver cancer cell proliferation.
3. Use according to claim 2, characterized in that: the liver cancer cell is selected from any one of the following: HepG2, PLC/PRF/5 and MHCC 97L.
4. Use according to claim 3, characterized in that:
the IC of Ramipril (Altace) for three liver cancer cells HepG2, PLC/PRF/5 and MHCC97L 50 96.8nM,25.1nM and 6.0. mu.M, respectively, in that order;
the IC of the ABT-737 to three hepatoma cells HepG2, PLC/PRF/5 and MHCC97L 50 184.0nM, 3.3. mu.M and 2.1. mu.M, respectively, in this order;
the IC of the Evacet rapib (LY2484595) on three liver cancer cells HepG2, PLC/PRF/5 and MHCC97L 50 This was followed by 9.2. mu.M, 5.6. mu.M and 2.0. mu.M, respectively.
5. Use according to any one of claims 2-4, characterized in that: the drug/compound targeting the SOAT1 protein is combined with the SOAT1 protein and influences the intracellular cholesterol homeostasis, so that the liver cancer cell proliferation is inhibited.
6. A product characterized by: the active ingredient of the product is selected from at least one of Ramipril (Altace), ABT-737 and Evactrapib (LY 2484595).
7. The product of claim 6, wherein:
the product has at least one of the following effects:
1) for preventing and/or treating liver cancer;
2) inhibiting proliferation of hepatocarcinoma cell;
the product is a medicament or pharmaceutical formulation.
8. The use of the drug/compound targeting the SOAT1 protein of claim 1 in:
1) preventing and/or treating liver cancer;
2) inhibiting proliferation of hepatocarcinoma cell.
9. Use according to claim 8, characterized in that: the liver cancer cell is selected from any one of the following: HepG2, PLC/PRF/5 and MHCC 97L.
10. A method for preventing and/or treating liver cancer, comprising the steps of: administering a drug/compound targeting the SOAT1 protein according to claim 1 or a product according to claim 6 or 7 to a recipient animal or human for the prevention and/or treatment of liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210544982.5A CN114917345A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110371783.4A CN112933235A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer |
| CN202210544982.5A CN114917345A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110371783.4A Division CN112933235A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114917345A true CN114917345A (en) | 2022-08-19 |
Family
ID=76232388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110371783.4A Pending CN112933235A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer |
| CN202210544982.5A Pending CN114917345A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110371783.4A Pending CN112933235A (en) | 2021-04-07 | 2021-04-07 | Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN112933235A (en) |
| WO (1) | WO2022213878A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112933235A (en) * | 2021-04-07 | 2021-06-11 | 北京蛋白质组研究中心 | Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer |
| CN115710301A (en) * | 2022-11-24 | 2023-02-24 | 陕西省中医药研究院 | SOAT1 protein targeted inhibitor and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6466130A (en) * | 1987-09-07 | 1989-03-13 | Sankyo Co | High polymer carcinostatic enhancer |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| US20120309744A1 (en) * | 2011-06-01 | 2012-12-06 | NBI Pharmaceuticals, Inc. | Dosing regimens and methods for treating or preventing hepatocellular carcinoma |
| CN103561726A (en) * | 2010-11-18 | 2014-02-05 | 通用医疗公司 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| CN109125324A (en) * | 2017-06-15 | 2019-01-04 | 北京蛋白质组研究中心 | Acyl-CoA: the new application of Cholesteryl acyltransferase 1 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101185633A (en) * | 2007-12-14 | 2008-05-28 | 山东蓝金生物工程有限公司 | Neratinib sustained-release implant for treating solid tumor |
| CN101336890A (en) * | 2008-05-30 | 2009-01-07 | 济南基福医药科技有限公司 | Anticancer sustained-release gel injection |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| CN102423483A (en) * | 2011-11-24 | 2012-04-25 | 西北农林科技大学 | Compound ramipril nano-emulsion for antihypertension |
| CN111273010B (en) * | 2018-12-04 | 2023-04-18 | 北京蛋白质组研究中心 | Application of kit for detecting SOAT1 protein expression level in preparation of hepatocellular carcinoma screening product |
| CN110101704A (en) * | 2019-05-28 | 2019-08-09 | 中国人民解放军军事科学院军事医学研究院 | Application of the c-Abl kinase inhibitor in FoxM1 high expression oncotherapy |
| CN112933235A (en) * | 2021-04-07 | 2021-06-11 | 北京蛋白质组研究中心 | Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer |
-
2021
- 2021-04-07 CN CN202110371783.4A patent/CN112933235A/en active Pending
- 2021-04-07 CN CN202210544982.5A patent/CN114917345A/en active Pending
-
2022
- 2022-03-31 WO PCT/CN2022/084430 patent/WO2022213878A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6466130A (en) * | 1987-09-07 | 1989-03-13 | Sankyo Co | High polymer carcinostatic enhancer |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| CN103561726A (en) * | 2010-11-18 | 2014-02-05 | 通用医疗公司 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| US20120309744A1 (en) * | 2011-06-01 | 2012-12-06 | NBI Pharmaceuticals, Inc. | Dosing regimens and methods for treating or preventing hepatocellular carcinoma |
| CN109125324A (en) * | 2017-06-15 | 2019-01-04 | 北京蛋白质组研究中心 | Acyl-CoA: the new application of Cholesteryl acyltransferase 1 inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022213878A1 (en) | 2022-10-13 |
| CN112933235A (en) | 2021-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102666553B (en) | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts | |
| CN102753185B (en) | Mangiferin-berberine salt, manufacturing method and use thereof | |
| Shan et al. | Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux | |
| CN114917345A (en) | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer | |
| CN106822168A (en) | Composition and its application method containing selenium organic compound | |
| CN102086172A (en) | Medicinal salts of saxagliptin and preparation methods of medicinal salts | |
| Zhang et al. | Discovery and evaluation of the hybrid of bromophenol and saccharide as potent and selective protein tyrosine phosphatase 1B inhibitors | |
| CN103860529B (en) | The purposes of auroglaucin compounds | |
| US20190040029A1 (en) | A type of aryl benzofuran amidated derivative and medical use thereof | |
| Xu et al. | BPN, a marine-derived PTP1B inhibitor, activates insulin signaling and improves insulin resistance in C2C12 myotubes | |
| CN107108603B (en) | Mangiferin -6-O- berberine salt and preparation method thereof and purposes | |
| Shakour et al. | Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents | |
| Qiu et al. | Inoscavin A, a pyrone compound isolated from a Sanghuangporus vaninii extract, inhibits colon cancer cell growth and induces cell apoptosis via the hedgehog signaling pathway | |
| Hou et al. | Establishment of a 3D hyperuricemia model based on cultured human liver organoids | |
| Hussain et al. | Molecular iodine-promoted oxidative cyclization for the synthesis of 1, 3, 4-thiadiazole-fused-[1, 2, 4]-thiadiazole incorporating 1, 4-benzodioxine moiety as potent inhibitors of α-amylase and α-glucosidase: In vitro and in silico study | |
| Sun et al. | An integrated approach for investigating pharmacodynamic material basis of Lingguizhugan Decoction in the treatment of heart failure | |
| CN111840561B (en) | Application of S100A9 inhibitor in preparation of medicine for treating pancreatitis | |
| Singh et al. | Discovery of triazole tethered thymol/carvacrol-coumarin hybrids as new class of α-glucosidase inhibitors with potent in vivo antihyperglycemic activities | |
| Ren et al. | Discovery novel VEGFA inhibitors through structure-based virtual screening and verify the ability to inhibit the proliferation, invasion and migration of gastric cancer | |
| EP4389756A1 (en) | Abiraterone derivative and preparation and application thereof | |
| Zhao et al. | Identification of natural product inhibitors of PTP1B based on high-throughput virtual screening strategy: In silico, in vitro and in vivo studies | |
| CN103172547B (en) | The preparation of sulfamide derivative and application thereof | |
| Yang et al. | Current screening, design, and delivery approaches to address low permeability of chemically synthesized modalities in drug discovery and early clinical development | |
| CN110776521A (en) | 1,2, 4-triazole-1, 3, 4-thiadiazole compound and application thereof | |
| CN111040018A (en) | Triptolide acrylate, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220819 |
|
| RJ01 | Rejection of invention patent application after publication |